Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic and Biological Effects of Imatinib Mesylate in Primary Hypereosinophilic Syndromes

NCT00787384 is registered in ClinicalTrials.gov with Northern Italy Leukemia Group as lead sponsor.

NCT NCT00787384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00787384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic and Biological Effects of Imatinib Mesylate in Primary Hypereosinophilic Syndromes
Lead sponsor
Northern Italy Leukemia Group
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2004
Completion date
December 31, 2007
Enrollment
25 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic eosinophilic leukemia, chronic idiopathic hypereosinophilia, hypereosinophilic syndrome